bumetanide has been researched along with Epilepsy, Temporal Lobe in 7 studies
Epilepsy, Temporal Lobe: A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In pentylenetetrazole-induced acute seizures only BUM532 combined with a sub-effective dose of PB increased the seizure threshold." | 3.96 | Functional characterization of novel bumetanide derivatives for epilepsy treatment. ( Auer, T; Erker, T; Schreppel, P; Schwarzer, C, 2020) |
| "According to our results, seizure frequency was reduced considerably in these patients." | 2.78 | Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. ( Beladimoghadam, N; Eftekhari, S; Gharakhani, M; Hadjighassem, MR; Hashemi Fesharaki, SS; Joghataei, MT; Mehvari Habibabadi, J; Mostafavi, H; Najafi Ziarani, M; Rahimian, E, 2013) |
| "Using a rat model of complex febrile seizures, which are thought to be a precipitating insult of TLE later in life, we report that aberrant migration of neonatal-generated granule cells results in granule cell ectopia that persists into adulthood." | 1.38 | GABAergic excitation after febrile seizures induces ectopic granule cells and adult epilepsy. ( Ichikawa, J; Ikegaya, Y; Koyama, R; Matsuki, N; Miyamoto, D; Muramatsu, R; Sasaki, T; Tao, K, 2012) |
| " Based on pharmacokinetic studies with bumetanide, which showed extremely rapid elimination and low brain penetration of this drug in rats, bumetanide was administered systemically with different dosing protocols, including continuous intravenous infusion." | 1.36 | Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. ( Brandt, C; Heuchert, N; Löscher, W; Nozadze, M; Rattka, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Auer, T | 1 |
| Schreppel, P | 2 |
| Erker, T | 2 |
| Schwarzer, C | 1 |
| Brandt, C | 2 |
| Töllner, K | 1 |
| Twele, F | 1 |
| Schidlitzki, A | 1 |
| Löscher, W | 2 |
| Berkovic, SF | 1 |
| Nozadze, M | 1 |
| Heuchert, N | 1 |
| Rattka, M | 1 |
| Koyama, R | 1 |
| Tao, K | 1 |
| Sasaki, T | 1 |
| Ichikawa, J | 1 |
| Miyamoto, D | 1 |
| Muramatsu, R | 1 |
| Matsuki, N | 1 |
| Ikegaya, Y | 1 |
| Eftekhari, S | 1 |
| Mehvari Habibabadi, J | 1 |
| Najafi Ziarani, M | 1 |
| Hashemi Fesharaki, SS | 1 |
| Gharakhani, M | 1 |
| Mostafavi, H | 1 |
| Joghataei, MT | 1 |
| Beladimoghadam, N | 1 |
| Rahimian, E | 1 |
| Hadjighassem, MR | 1 |
| Palma, E | 1 |
| Amici, M | 1 |
| Sobrero, F | 1 |
| Spinelli, G | 1 |
| Di Angelantonio, S | 1 |
| Ragozzino, D | 1 |
| Mascia, A | 1 |
| Scoppetta, C | 1 |
| Esposito, V | 1 |
| Miledi, R | 1 |
| Eusebi, F | 1 |
1 review available for bumetanide and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
Epilepsy research in 2016: new treatment directions.
Topics: Biomedical Research; Bumetanide; Drug Resistant Epilepsy; Epilepsy; Epilepsy, Temporal Lobe; Humans; | 2017 |
1 trial available for bumetanide and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy.
Topics: Adult; Anticonvulsants; Bumetanide; Electroencephalography; Epilepsy, Temporal Lobe; Humans; Male; S | 2013 |
5 other studies available for bumetanide and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
Functional characterization of novel bumetanide derivatives for epilepsy treatment.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Brain; Bumetanide; Convulsants; Disease Models, Anima | 2020 |
The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.
Topics: Animals; Anticonvulsants; Bumetanide; Convulsants; Disease Models, Animal; Dose-Response Relationshi | 2016 |
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
Topics: Amygdala; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Bumetanide; Cell Count; | 2010 |
GABAergic excitation after febrile seizures induces ectopic granule cells and adult epilepsy.
Topics: Animals; Animals, Suckling; Brain Diseases; Bumetanide; Cell Lineage; Cell Movement; Choristoma; Den | 2012 |
Anomalous levels of Cl- transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory.
Topics: Animals; Bumetanide; Epilepsy, Temporal Lobe; Excitatory Postsynaptic Potentials; gamma-Aminobutyric | 2006 |